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Objectives. Cyclosporine A (CyA), tacrolimus (TRL), sirolimus (SIR), and everolimus (RAD) are immunosuppressive drugs fre-
quently used in organ transplantation. Our aim was to conﬁrm a robust sensitive and selective liquid chromatography-tandem
mass spectrometry (LC-MS/MS) method for determination of CyA, TRL, SIR, and RAD in whole-blood samples. Materials and
Methods. We used an integrated online solid-phase extraction-LC-MS/MS system and atmospheric pressure ionization tandem
mass spectrometry (API-MS/MS) in the multiple reaction monitoring (MRM) detection mode. CyA, TRL, SIR, and RAD
were simultaneously analyzed in whole blood treated with precipitation reagent taken from transplant patients. Results.S y s t e m
performance parameters were suitable for using this method as a high-throughput technique in clinical practice. The high concen-
tration of one analyte in the sample did not aﬀect the concentration of other analytes. Total analytical time was 2.5min, and
retention times of all analytes were shorter than 2 minutes. Conclusion. This LC-MS/MS method can be preferable for therapeutic
drugmonitoringoftheseimmunosuppressivedrugs(CyA,TRL,SRL,andRAD)inwholeblood.Samplepreparationwastooshort
and simple in this method, and it permits robust, rapid, sensitive, selective, and simultaneous determination of these drugs.
1.Introduction
Cyclosporine A (CyA), tacrolimus (TRL), sirolimus (SRL),
and everolimus (RAD) are the most frequently used immu-
nosuppressive drugs in organ transplantation [1]. CyA and
TRL act as calcineurin inhibitors and cause lymphocyte pro-
liferation downstream via cytokine production suppressing
[2]. SRL and RAD inhibit T-cell cycle progression by block-
ing interleukin-2 production [3]. These immunosuppressive
drugs have narrow therapeutic ranges. They may cause nu-
merous side eﬀects including immunological, renal, hepatic,
and neurological complications, requiring dose adjustment
or discontinuation in a signiﬁcant percentage of patients [4,
5]. In addition, there is important variation for blood levels
of these immunosuppressive drugs in diﬀerent individuals,
andethnicitiesmayalsoaﬀecttheseparameters[6,7].There-
fore, therapeutic drug monitoring (TDM) plays a key role in
maintaining therapeutic blood and plasma levels of immu-
nosuppressive drugs, which has narrow therapeutic ranges
for reducing their risk of toxicity and organ rejection [8].
TDM has been used to monitor drug levels in routine patient
care. The methodology of TDM must be precise and accu-
rate for immunosuppressive drugs [9]. Immunosuppressive
drugs have some complementary mechanisms of action and2 The Scientiﬁc World Journal
interactsynergisticallywhenusedtogether;thereforetheyare
often combined in clinical practice [4]. Due to increasing
number of transplant patients and of combined drugs used,
simultaneous determination of these drugs is required for
routine TDM.
Therearetwomainanalyticalmethodsfordetermination
of immunosuppressive drugs in transplant patients: immu-
noassays (microparticle enzyme immunoassay, cloned enzy-
me donor immunoassay, etc.) and liquid chromatography-
based methods (high-performance liquid chromatography
(HPLC) with ultraviolet detection, LC-mass spectrometry
(LC-MS), and LC-tandem mass spectrometry (LC-MS/MS))
[10]. Traditionally most routine laboratories use immuno-
logical methods for quantiﬁcation of immunosuppressive
drugs. Due to cross-reactions with some metabolites of these
drugs, overestimation of the concentrations is a major pro-
blem in immunological techniques [9, 11]. LC-MS/MS has
some advantages compared to other methods, and its cost
has also been decreased, recently. This method is more speci-
ﬁc and sensitive than immunological methods for these im-
munosuppressive drugs. Simultaneous measurements of se-
veral drugs can also be possible with LC-MS/MS technique
[7]. Because of the above mentioned reasons, LC-MS/MS is
generally accepted as the technique of choice [12]. Various
LC-MS and LC-MS/MS methods have been developed and
used for TDM in daily clinical routine laboratories [11–23].
The aim of this study was to conﬁrm a rapid, sensitive,
selective, and cost-eﬀective LC-MS/MS method, which is
able to measure CyA, TRL, SRL, and RAD in whole-blood
samples for the purpose of TDM.
2. Methods
The method described by Koal et al. was established in our
laboratory for determination of CyA, TRL, SRL, and RAD
in this study [14]. EDTA-treated excess blood specimens of
organ transplant patients (kidney and bone marrow) were
analyzed immediately in the same day at the LC-MS/MS
laboratory. All analyses performed within 6 hours of venous
blood drawing.
2.1. Chemicals. HPLC grade methanol, ammonium acetate,
and zinc sulfate heptahydrate were purchased from Merck
(Darmstadt, Germany), and acetic acid was provided from
Riedel-de Haen (Hannover-Seelze, Germany). Ultrapure
water was supplied by a Milli-Q Water Puriﬁcation System
from Millipore (Molsheim, France). Ascomycin, SRL, RAD,
TRL, Cyclosporine D (CyD), and CyA were obtained from
ImmuChrom(Heppenheim,Germany).Allreagentsandsol-
v e n t sw e r eo fa n a l y t i c a lg r a d e .
Commercially available whole-blood calibrators (6 mul-
tilevel calibrator set) and quality control (QC) samples
(three-level whole blood controls) were purchased from Im-
muchrom(Heppenheim,Germany).Theywereusedforcali-
bration of CyA, SRL, TRL, and RAD assays. Concentration
ranges were between 0 and 39.70ng/mL (0.0, 1.22, 2.46,
5.03, 10.20, and 39.70) for TRL, between 0 and 44.30ng/mL
(0.0, 1.38, 2.71, 5.41, 11.30, and 44.30) for SRL, between
0 and 44.90ng/mL (0.0, 1.20, 2.62, 5.13, 10.90, and 44.90)
for RAD, and between 0 and 1345ng/mL (0.0. 24.30, 48.40,
92.40, 187.0, and 1345.0) for CyA. All calibrators and quali-
ty control samples were aliquoted in 100µL portions in ep-
pendorf tubes and immediately stored at −80◦C until ana-
lysis.Batcheswerestableforat least90 days.One hourbefore
samplepreparation,onebatchofcalibratorsandqualitycon-
trol samples were thawed. The usage of commercial calibra-
tors eliminates an important source of random errors, com-
pared to the preparation of “in house” standards.
2.2. Sample Preparation. Precipitation reagent including in-
ternal standards (ascomycin and CyD) was prepared imme-
diately before sample preparation. Precipitation reagent used
in this study was methanol/1.125M ZnSO4 in water (66/34,
v/v) including 20ng/mL Ascomycin and 125ng/mL CyD. All
specimens (EDTA-treated whole blood samples, calibrators,
and controls) were put into a 1.5mL conical test tube as
100µL volume and 200µL precipitation reagent was added.
Samples were immediately vortexed 30sec and left 5min at
the room temperature. After vortexing for additional 5sec,
the tubes were centrifuged for 10min at 15000×ga t4 ◦C.
Supernatants were transferred into the autosampler vials.
Thetemperatureofautosamplerwasadjustedat20◦Cduring
the analysis for providing standard experimental conditions.
2.3. Instrumentation. A Shimadzu Prominence series Ultra
Fast Liquid Chromatography (UFLC) system (Kyoto, Japan)
equipped with a temperature controlled autosampler (Shi-
madzu Prominence Series SIL 20AC HT, autosampler) was
used. Two isocratic UFLC pumps (Shimadzu Prominence 20
AD series pump, Kyoto, Japan) were used. HPLC separation
was performed with column switching system and two
isocratic UFLC pumps (Shimadzu Prominence 20 AD series
pump, Kyoto, Japan). 10-port valve (Valco) controlled by a
software were used for column switching, but only seven of
these ports were used (Figure 1).
2.4. LC-MS/MS. It has been shown that combination of LC
and tandem mass spectrometry has advantage of simulta-
neous measurement of diﬀerent immunosuppressive drugs
[16].ButuseofthesemethodsinroutineTDMhassomedis-
advantages, for example, extraction of drugs from blood
requires long time. For the sake of robust and rapid cleaning
procedure, automatic online solid phase extraction was used
in this study.
Foronlinesampleclean-up,aperfusioncolumn(POROS
R1/20, 2.1 × 30mm, 20µm particle size, Applied Biosys-
tems, Darmstadt, Germany) was used. The use of this
column provides high rate of washing, ﬂushing, and re-equi-
libration, so that there was no waste of time between SPE
and chromatographic separation. Phenyl Hexyl RP col-
umn (Phenomenex Luna 5µmp a r t i c l es i z e ,2× 50mm,
Aschaﬀenburg, Germany) was used as an analytical col-
umn. HPLC separation was performed at 60◦Cw i t ha n
HPLC-column oven (Shimadzu Prominence, CTO 10 AS
vp Column oven). A triple quadrupole mass spectrometer
(API3200AppliedBiosystems/MDSSciexConcord,Canada)
with TurboIonSpray source (ESI) was used in positive ionThe Scientiﬁc World Journal 3
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Figure 1: Column switching procedure of the online SPE-LC-MS/MS setup: (a) sample loading and clean-up; (b) sample elution from the
analytical column.4 The Scientiﬁc World Journal
Table 1: Timetable for pump conﬁguration.
Time (min) Flow rate (µL/min)
Eluent A Eluent B
0.00 300 400
0.05 4500 300
0.75 4500 400
0.80 4500 300
0.85 300 300
2.20 300 300
2.25 4500 300
2.45 3300 300
2.50 300 300
Eluent A: MeOH/H2O (50/50, v/v); eluent B: MeOH/H2O (97/3, v/v;
10mmol/L CH3COONH4, 0.1% acetic acid).
mode. Multiple reaction mode (MRM) was performed for
all specimens.
Loading and injecting diagrams for the samples on the
switchingvalveforonlineSPEcolumnareshowninFigure 1.
Two mobile phases, eluent A (MeOH/H2O (50/50, v/v))
and eluent B (high organic solvent, MeOH/H2O 97/3, v/v
(10mmol/L CH3COONH4, 0.1% acetic acid)), were ﬂowed
by the pump A and the pump B, respectively. Sample clean-
up on SPE column and rinsing step is shown in Figure 1(a).
At the beginning of chromatography, 50µL sample was in-
jected into the system. After injecting the samples, the ﬂow
rate of eluent A was 4500µL/min and the ﬂow rate of eluent
B was 400µL/min for the ﬁrst 0.8min. The ﬂow of eluent
A enriched the sample on SPE column, and the ﬂow of
eluent B entered and equilibrated analytical column in this
same period (Figure 1(a)). At 0.8min after injecting of the
samples, the position of valves switched from Figure 1(a)
to Figure 1(b). The ﬂow rates of both eluent A and B were
changed to 300µL/min in this period. The timetable of ﬂow
rates for the two conﬁgured isocratic pumps was shown in
Table 1. The position of switching valve returned back as
shown in Figure 1(a) at 2.3min. Until next injection, this
position remained constant for re-equilibration.
In this combined system, fast and reliable extraction pro-
cedure was performed, and the analytes were eluted from
the precolumn to the analytical column by eluent B. High
organic content the eluent B (MeOH/H2O 97/3, 10mmol/L
CH3COONH4, 0.1% acetic acid) is compatible with Tur-
boIonSpray source and provides reduced band extension.
Multiple reaction monitoring (MRM) mode is used for
analytes with similar retention times because of eluent B is
not enough to separate the analytes in phenyl-hexyl column.
Table 2 shows the retention times of immunosuppressive
drugs. The total run time of online SPE, LC-MS/MS detec-
tion, and equilibrium was 2.5min for all analytes, including
two internal standards.
Mass spectrometric detection with a TurboIonSpray in-
terface was used for detection of the immunosuppressive
drugs. The turbogas temperature was set at 325◦C, and the
ion spray voltage was adjusted to 5500V. High-purity nitro-
gen was used as curtain gas (20psi) and collision gas (8psi).
Air was used as nebulizer gas (12psi) and drying gas. The
mass spectrometer was operated at unit resolution for both
quantiﬁer and qualiﬁer in the MRM mode, with a dwell time
of 40ms per MRM channel. API 3200 MS/MS parameters
of declustering potential (DP), entrancepotential (EP),colli-
sioncellentrancepotential(CEP),collisionenergy(CE),col-
lision cell exit potential (CXP), and the retention times
werepresentedinTable 2 foralltargetedimmunosuppressive
drugsandinternalstandards.Analyst1.4.2softwarewasused
for the control of equipment, data acquisition, and analysis.
3. Results
An LC-MS/MS assay permits robust, rapid, sensitive, selec-
tive and simultaneous quantiﬁcation of four immunosup-
pressive drugs (CyA, TRL, SRL, and RAD) in whole-blood
samples. We used online extraction of samples, a short phen-
yl hexyl analytic column and mobile phase containing high
organic solvent, so that the total analysis time was less than
2.5min for all analytes. The ion chromatograms of all im-
munosuppressive drugs extracted from both control and
patient whole blood samples are shown in Figure 2.
For system performance evaluation, we determined the
limits of detection (LOD), the lower limits of quantiﬁcation
(LOQ),thesquaredcorrelationcoeﬃcients(R2),therecovery
rates, the relative standard deviation values (R.S.D.), and the
accuracy values. LOD and LOQ were estimated by inject-
ing whole blood samples spiked with the analytes at low con-
centrations. The LOD was set on the basis of a 3:1 signal-
to-noise ratio, and the LOQ was estimated on the basis of a
10:1 signal-to-noise ratio. The LOD was 1.4µg/L for TRL,
0.72µg/L for SRL, 1.15µg/L for RAD, and 5.6µg/L for CyA.
The LOQ was 4.0µg/L for TRL, 1.8µg/L for SRL, 3.1µg/L for
RAD, and 15.4µg/L for CyA. The assay was linear over the
range of 4–250µg/L for TRL (r2 = 0.9998), 1.8–250µg/L for
SRL (r2 = 0.9998), 3.1–250µg/L for RAD (r2 = 0.9998) and
15.4–4400µg/L for CyA (r2 = 0.9998) (Table 3).
The analytical recovery results for CyA, TRL, SRL, and
RAD at low concentrations were 102.1%, 95.0%, 94.3%, and
95.9%, respectively. The analytical recovery results for high
concentrations of CyA, TRL, SRL and RAD were 98.5%,
92.8%, 95.7% and 94.9%, respectively (Table 3). The com-
mercialcontrolwholebloodsamplesthathavethreediﬀerent
concentrations of immunosuppressive drugs were measured
20 times in the same run for intraday precision and were
measured20timesinconsecutivedaysforinterdayprecision.
The results of these precision measurements were presented
in Table 3.C o e ﬃcient of Variation (CV) for intraday pre-
cision was below 5% for all analytes and concentrations. CV
for inter-day precision did not exceed 4.5% for SRL, 4.3%
for TRL, 5.9% for RAD, and 6.2% for CyA. Determination of
mean accuracy of CyA, TRL, SRL, and RAD measurements
was studied at commercial whole blood control samples,
which was calculated to be 100.2%, 99%, 100.3% and 97.9%,
respectively (Table 3).
To avoid sample matrix eﬀects, online SPE and LC-
MS/MS were used together. Phenyl-Hexyl analytical column
with high organic solvent mobile phase (methanol/water
97/3, v/v) was used in this system for eliminating residualThe Scientiﬁc World Journal 5
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Figure 2: Extracted ion chromatograms of (a) cyclosporin A, (b) tacrolimus, (c) sirolimus, and (d) everolimus from whole blood control
and (e) cyclosporin A from patient sample.6 The Scientiﬁc World Journal
Table 2: LC-MS/MS parameters (MRM transition, DP, EP, CEP, CE, and CXP) and retention times of four immunosuppressive drugs and
internal standards.
CyA TRL SRL RAD Ascomycin IS CyD IS
MRM-transition 1202.80 → 425.20 821.60 → 768.50 931.66 → 864.50 975.65 → 908.50 809.59 → 756.40 1216.90 → 425.50
DP (V) 100.00 50.63 41.25 44.38 50.63 110.00
E P ( V ) 1 01 01 01 01 01 0
CEP (V) 39.85 34.88 38.52 39.97 34.49 47.93
CE (V) 68 29 23 250 29 69
C X P ( V ) 4 1 21 41 41 2 4
Retention time (min) 1.97 1.81 1.84 1.85 1.81 2.00
Retention time RSD%
(min) 0.245 0.137 0.186 0.142 0.148 0.236
CyA: cyclosporin A, TRL: tacrolimus, SRL: sirolimus, RAD: everolimus, CyD: cyclosporin D, IS: internal Standard, MRM: multiple reaction monitoring, DP:
declustering potential, EP: entrance potential, CEP: collision cell entrance potential, CE: collision energy, CXP: collision cell exit potential,a n dV :v o l t .
Table 3: Method performance parameters.
CyA TRL SRL RAD
LOD (µg/L) 5.6 1.4 0.72 1.15
LOQ (µg/L) 15.4 4 1.8 3.1
Linearitya (R2) 0.9998 0.9998 0.9998 0.9998
Recoveryb (%)
Concentration 1 102.1 95 94.3 95.9
Concentration 2 98.5 92.8 95.7 94.9
Intraday CV (%) (LI)c 3.2 2.8 3.2 2.4
Interday CV (%) (LI)c 3.2 4.3 4.5 4.1
Intraday CV (%) (LII)d 3.3 2.2 2.1 1.7
Interday CV (%) (LII)d 4.7 4.3 4.3 5.9
Intraday CV (%) (III)e 4.5 3.5 4.8 3.0
Interday CV (%) L(III)e 6.2 3.8 3.0 3.99
Accuracy (%) 100.2 99.0 100.3 97.9
CyA: cyclosporin A, TRL: tacrolimus, SRL: sirolimus, RAD: everolimus, and
LOD: limit of detection, LOQ: lover limits of quantiﬁcation.
ac = 15.4–4400µg/L (CyA), 1.8–250µg/L (SRL), 3.1–200µg/L (RAD), and
4–200µg/L (TRL).
bc1 = 100µg/L (CyA), c1 = 10µg/L (SRL, RAD, TRL), c2 = 500µg/L (CyA),
and c2 = 100µg/L for (SRL, RAD, and TRL).
cc = 50µg/L (CyA), c = 4µg/L (TRL), c = 1.8µg/L (SRL), c = 3.1µg/L
(RAD).
dc = 100µg/L (CyA), c = 20µg/L (TRL), c = 7.2µg/L (SRL), and c =
12.4µg/L (RAD).
ec = 500µg/L (CyA), c = 40µg/L (TRL), c = 18µg/L (SRL), and c = 31µg/L
(RAD).
interfering eﬀects of the blood matrix [14, 16]. Thus residual
matrix interferences passed the column without retentions.
The ion chromatograms of all immunosuppressive drugs
extracted from a control whole blood and a patient’s whole
blood for each analyte are shown in Figure 2. Because of the
very short total analysis time (2.5min), the peaks of each
immunosuppressive drug in the chromatogram were not
chromatographically separated from each other (Table 1).
Therefore, the peaks of each immunosuppressive drug were
separated with MRM mode. There were no ion suppression
eﬀects of analytes to each other.
4. Discussion
In this study, we used combination of online SPE and LC-
MS/MS for simultaneous determination of four immuno-
suppressive drugs in whole blood samples of patients with
organ transplantation. This method has some advantages
compared to oﬄine SPE LC-MS/MS and immunoassays. In
this method, there is no overestimation of drugs concen-
trations due to nonspeciﬁc cross-reaction from their meta-
bolites encountered in immunoassays [10]. The total proce-
dure of online SPE LC-MS/MS method is very simple and
requires short time unlike oﬄine SPE LC-MS/MS. LC-MS/
MS has high speciﬁcity and sensitivity for determining drugs
concentrations and has been used as standard method for
TDM. Additionally, the measurement of more than one drug
from the same sample is possible in this chromatographic
method. But usage of LC-MS/MS method for TDM in
routine clinical practice may be limited due to the following
factors: the ﬁrst establishment of instruments can be costly;
highly trained personnel are required; total analysis time
from sample preparation until results are achieved is longer.
Combining online SPE with LC-MS/MS method has the
following advantages: minimizing the matrix eﬀect due to
fast and simple extraction procedure, noise reduction, limi-
tation of unspeciﬁc peaks, and more samples analyzing with
one analytical column. Therefore, compared to oﬄine SPE
LC-MS/MS technique, online SPE LC-MS/MS is more useful
for routine TDM in clinical practice [11, 16].
We used a short phenyl-hexyl reverse phase column as
analytical column and high ﬂow rate of high organic solvent
(methanol/water97/3,v/v)asamobilephase,sothattheelu-
tion time of all immunosuppressive drugs was shorter than
2min. Because of this short analytical time, there were no re-
tention time diﬀerences for all immunosuppressive drugs. To
solve this problem, MRM detection mode of LC-MS/MS was
used, which allows eﬀective separation of chromatographic
peaks.
Interfering eﬀects of the sample matrix are an important
problem in quantiﬁcation of these four immunosuppressive
drugs. In this study, better matrix component elimination
wasachievedbyusingonlineSPEinfrontofLC-MS/MSana-
lysis compared to direct LC-MS/MS analysis. Additionally,The Scientiﬁc World Journal 7
the blood matrix was also eliminated with the help of a
phenyl-hexyl reverse-phasecolumn andmobile phase, which
contain high organic solvent [14, 16]. Therefore, the residue
of matrix passed the column without retentions.
We analyzed more than 1000 whole blood samples with
one perfusion column for online SPE and one phenyl-hexyl
column for LC-MS/MS analyses at 60◦C. In the evaluation of
analytical column performance, we observed that there were
no peak broadening, peak tailing, peak splitting, increased
pressure of the column, or shifting on retention times of all
analytes.
As a conclusion, we have described an online SPE-LC-
MS/MSmethodforsimultaneousdeterminationsofpresent-
ly interesting four immunosuppressive drugs (CyA, TRL,
SRL, and RAD) in whole blood samples. In this method the
sample preparation procedure was extremely simple, the cost
of total analyses was very low, and the time needed to per-
form these measurements was very short. To reduce time
of analyses and to solve sample matrix problems, we used
online SPE perfusion column combined with a short phenyl-
hexyl analytical column and MRM mode of highly selective
MS/MS. This method also provided low CV levels for intra-
day and interday precisions and speciﬁcity and sensitivity.
This method permits robust, simultaneous, and low-cost
analyses of TDM with multiple immunosuppressive drugs.
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